1
|
Yang L, Yin X, Li Z, Ding Z, Zou Y, Li Z, Mo E, Zhou Q, Wang J, Hu W. Adaptive radiotherapy triggering for nasopharyngeal cancer based on bayesian decision model. Phys Med Biol 2025; 70:075015. [PMID: 40101364 DOI: 10.1088/1361-6560/adc238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2024] [Accepted: 03/18/2025] [Indexed: 03/20/2025]
Abstract
Objective.To develop a Bayesian decision model for adaptive radiotherapy (ART) in nasopharyngeal cancer (NPC) that balances clinical capacity of ART and inter-fraction dosimetric changes.Approach.A retrospective analysis was conducted on 84 fractions from 17 NPC patients treated with intensity-modulated radiotherapy using a CT-Linac. Fourteen patients were included for the model construction, and three for validation. Daily diagnostic-level CT images were rigidly registered to the planning CT for regions of interest and treatment plan propagation. The propagated contours were reviewed and refined by radiation oncologists. For each daily CT, percentage differences in 27 dose metrics were compared to the original plan. Composite scores of dose differences were developed using factor analysis on planning target volume (PTV) and organ at risk (OAR) dose metrics. These scores were integrated into a Bayesian decision model, which incorporated a subjective trigger rate to determine the initiation of ART.Main results.The model generated individualized re-plan strategies based on composite scores for PTV or OAR, with trigger rates ranging from 10% to 60%. In the validation with 14 fractions, significant anatomical and dosimetric variations were identified. At a 30% trigger rate, only one fraction was misclassified.Significance.It is feasible to employ a Bayesian decision model for ART, merging subjective clinical insights with objective dosimetric data to refine re-planning decisions.
Collapse
Affiliation(s)
- Long Yang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Xiaojie Yin
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Zhenhao Li
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Zhiyu Ding
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Yue Zou
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Ziwei Li
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Enwei Mo
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Qingyuan Zhou
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Jiazhou Wang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| | - Weigang Hu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai 200032, People's Republic of China
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, People's Republic of China
| |
Collapse
|
2
|
Choulilitsa E, Bobić M, Winey B, Paganetti H, Lomax AJ, Albertini F. Multi-institution investigations of online daily adaptive proton strategies for head and neck cancer patients. Phys Med Biol 2025; 70:065012. [PMID: 40014924 DOI: 10.1088/1361-6560/adbb51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2024] [Accepted: 02/27/2025] [Indexed: 03/01/2025]
Abstract
Objective.Fast computation of daily reoptimization is key for an efficient online adaptive proton therapy workflow. Various approaches aim to expedite this process, often compromising daily dose. This study compares Massachusetts General Hospital's (MGH's) online dose reoptimization approach, Paul Scherrer Institute's (PSI's) online replanning workflow and a full reoptimization adaptive workflow for head and neck cancer (H&N) patients.Approach.Ten H&N patients (PSI:5, MGH:5) with daily cone beam computed tomographys (CBCTs) were included. Synthetic CTs were created by deforming the planning CT to each CBCT. Targets and organs at risk (OARs) were deformed on daily images. Three adaptive approaches were investigated: (i) an online dose reoptimization approach modifying the fluence of a subset of beamlets, (ii) full reoptimization adaptive workflow modifying the fluence of all beamlets, and (iii) a full online replanning approach, allowing the optimizer to modify both fluence and position of all beamlets. Two non-adapted (NA) scenarios were simulated by recalculating the original plan on the daily image using: Monte Carlo for NAMGHand raycasting algorithm for NAPSI.Main results.All adaptive scenarios from both institutions achieved the prescribed daily target dose, with further improvements from online replanning. For all patients, low-dose CTV D98%shows mean daily deviations of -2.2%, -1.1%, and 0.4% for workflows (i), (ii), and (iii), respectively. For the online adaptive scenarios, plan optimization averages 2.2 min for (iii) and 2.4 for (i) while the full dose reoptimization requires 72 min. The OAMGH20%dose reoptimization approach produced results comparable to online replanning for most patients and fractions. However, for one patient, differences up to 11% in low-dose CTV D98%occurred.Significance.Despite significant anatomical changes, all three adaptive approaches ensure target coverage without compromising OAR sparing. Our data suggests 20% dose reoptimization suffices, for most cases, yielding comparable results to online replanning with a marginal time increase due to Monte Carlo. For optimal daily adaptation, a rapid online replanning is preferable.
Collapse
Affiliation(s)
- Evangelia Choulilitsa
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland
- Department of Physics, ETH Zurich, Zurich, Switzerland
| | - Mislav Bobić
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Brian Winey
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Antony J Lomax
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland
- Department of Physics, ETH Zurich, Zurich, Switzerland
| | | |
Collapse
|
3
|
Heilemann G, Zimmermann L, Nyholm T, Simkó A, Widder J, Goldner G, Georg D, Kuess P. Ultra-fast, one-click radiotherapy treatment planning outside a treatment planning system. Phys Imaging Radiat Oncol 2025; 33:100724. [PMID: 40026911 PMCID: PMC11870257 DOI: 10.1016/j.phro.2025.100724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2024] [Revised: 02/04/2025] [Accepted: 02/04/2025] [Indexed: 03/05/2025] Open
Abstract
We present an automated radiation oncology treatment planning pipeline that operates between segmentation and plan review, minimizing manual interaction and reliance on traditional planning systems. Two AI models work in sequence: the first generates a dose distribution, and the second creates a deliverable DICOM-RT plan. Trained and validated on 276 plans, and tested on 151 datasets, the system produced clinically deliverable plans-complete with all VMAT parameters-in about 38 s. These plans met target coverage and most organ-at-risk constraints. This proof-of-concept demonstrates the feasibility of generating high-quality, deliverable DICOM plans within seconds.
Collapse
Affiliation(s)
- Gerd Heilemann
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| | - Lukas Zimmermann
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| | - Tufve Nyholm
- Department of Diagnostics and Intervention, Umeå University 90185 Umeå, Sweden
| | - Attila Simkó
- Department of Diagnostics and Intervention, Umeå University 90185 Umeå, Sweden
| | - Joachim Widder
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| | - Gregor Goldner
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| | - Dietmar Georg
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| | - Peter Kuess
- Department of Radiation Oncology, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
| |
Collapse
|
4
|
Schneider M, Gutwein S, Mönnich D, Gani C, Fischer P, Baumgartner CF, Thorwarth D. Development and comprehensive clinical validation of a deep neural network for radiation dose modelling to enhance magnetic resonance imaging guided radiotherapy. Phys Imaging Radiat Oncol 2025; 33:100723. [PMID: 40093656 PMCID: PMC11908596 DOI: 10.1016/j.phro.2025.100723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Revised: 02/04/2025] [Accepted: 02/04/2025] [Indexed: 03/19/2025] Open
Abstract
Background and purpose Online adaptive magnetic resonance imaging (MRI)-guided radiotherapy requires fast dose calculation algorithms to reduce intra-fraction motion uncertainties and improve workflow efficiency. While Monte-Carlo simulations are precise but computationally intensive, neural networks promise fast and accurate dose modelling in strong magnetic fields. This study aimed to train and evaluate a deep neural network for dose modelling in MRI-guided radiotherapy using a comprehensive clinical dataset. Materials and methods A dataset of 6595 clinical irradiation segments from 125 1.5 T MRI-Linac radiotherapy plans for various tumors sites was used. A 3D U-Net was trained with 3961 segments using 3D imaging data and field parameters as input, Root Mean Squared Error and a custom loss function, with full Monte-Carlo simulations as ground truth. For 2656 segments from 50 patients, gamma pass rates (γ-PR) for 3 mm/3%, 2 mm/2%, and 1 mm/1% criteria were calculated to assess dose modelling accuracy. Performance was also tested in a standardized water phantom to evaluate basic radiation physics properties. Results The neural network accurately modeled dose distributions in both patient and water phantom settings. Median (range) γ-PR of 97.7% (87.5-100.0%), 89.1% (69.7-99.4%), and 60.8% (38.5-82.1%) were observed for treatment plans, and 97.1% (55.5-100.0%), 88.8% (38.8-99.7%), and 61.7% (17.9-94.4%) for individual segments, across the three criteria. Conclusion High median γ-PR and accurate modelling in both water phantom and clinical data demonstrate the high potential of neural networks for dose modelling. However, instances of lower γ-PR highlight the need for comprehensive test data, improved robustness and future built-in uncertainty estimation.
Collapse
Affiliation(s)
- Moritz Schneider
- Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
| | - Simon Gutwein
- Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
| | - David Mönnich
- Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
| | - Cihan Gani
- Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
| | - Paul Fischer
- Cluster of Excellence "Machine Learning: New Perspectives for Science", University of Tübingen, Germany
- Faculty of Health Sciences and Medicine, University of Lucerne, Switzerland
| | - Christian F Baumgartner
- Cluster of Excellence "Machine Learning: New Perspectives for Science", University of Tübingen, Germany
- Faculty of Health Sciences and Medicine, University of Lucerne, Switzerland
| | - Daniela Thorwarth
- Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany
- Cluster of Excellence "Machine Learning: New Perspectives for Science", University of Tübingen, Germany
- German Cancer Consortium (DKTK), partner site Tübingen, a partnership between DKFZ and University Hospital Tübingen, Germany
| |
Collapse
|
5
|
Oud M, Breedveld S, Giżyńska M, Chen YH, Habraken S, Perkó Z, Heijmen B, Hoogeman M. Dosimetric advantages of adaptive IMPT vs. Enhanced workload and treatment time - A need for automation. Radiother Oncol 2024; 201:110548. [PMID: 39343389 DOI: 10.1016/j.radonc.2024.110548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2024] [Revised: 09/19/2024] [Accepted: 09/23/2024] [Indexed: 10/01/2024]
Abstract
INTRODUCTION In head-and-neck IMPT, trigger-based offline plan adaptation (Offlinetrigger-based) is often used. Our goal was to compare this to four alternative adaptive strategies for dosimetry, workload and treatment time, considering also foreseen further technological advancements, including anticipated automation. MATERIALS AND METHODS Alternative strategies included weekly offline re-planning (Offlineweekly), daily plan selection from a library (Librarystatic and Libraryprogsressive) and a fast, approximate daily online re-optimization approach (Onlinere-opt). Impact on CTV coverage and NTCPs was assessed by simulations based on repeat-CTs from 15 patients. Full daily re-planning was used as dosimetric benchmark. Increases in workload and treatment time were estimated. RESULTS Both for coverage and NTCPs, fast Onlinere-opt performed as well as full re-planning. Compared to current practice, Onlinere-opt showed enhanced probabilities for high coverage, and resulted in reductions in grade ≥ II NTCPs of 4.6 ± 1.7 %-point for xerostomia and 4.2 ± 2.3 %-point for dysphagia. Offlineweekly and library strategies did not show coverage enhancements and resulted in smaller NTCP improvements. Further automation can largely limit workload and treatment time increases. With anticipated further automation, adaptation-related workload of Offlineweekly, Librarystatic, Libraryprogressive, and Onlinere-opt was expected to increase by 3, 8, 21, and 66 h for 35 fraction treatment courses compared to Offlinetrigger-based. The corresponding adaptation-related prolonged treatment times were estimated to be 0, 4, 6, and 29 min/fraction. CONCLUSION Online adaptive strategies could approach dosimetric quality of full re-planning at the cost of additional workload and prolonged treatment time compared to the current offline adaptive strategy. Automation needs to play a key role in making more complex adaptive approaches feasible.
Collapse
Affiliation(s)
- Michelle Oud
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands; HollandPTC, Delft, Netherlands.
| | - Sebastiaan Breedveld
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands
| | | | - Yi Hsuan Chen
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Netherlands
| | - Steven Habraken
- HollandPTC, Delft, Netherlands; Leiden University Medical Center, Department of Radiation Oncology, Leiden, Netherlands
| | - Zoltán Perkó
- Delft University of Technology, Faculty of Applied Sciences, Department of Radiation Science and Technology, Netherlands
| | - Ben Heijmen
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands
| | - Mischa Hoogeman
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands; HollandPTC, Delft, Netherlands
| |
Collapse
|
6
|
Calvo-Ortega JF, Laosa-Bello C, Moragues-Femenía S, Pozo-Massó M, Jones A. Experience with patient-specific quality assurance of dosimetrist-led online adaptive prostate SBRT. J Med Imaging Radiat Sci 2024; 55:101719. [PMID: 39084157 DOI: 10.1016/j.jmir.2024.101719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 05/30/2024] [Accepted: 06/27/2024] [Indexed: 08/02/2024]
Abstract
INTRODUCTION The aim of this study was to assess the results of the local pre-treatment verifications of online adaptive prostate SBRT plans performed by dosimetrists METHODS AND MATERIALS: Prostate SBRT treatments are planned in our department using an online adaptive method developed and validated by our group. The adaptive plans were computed on the daily CBCT scan using the Acuros XB v. 16.1 algorithm of the Varian Eclipse treatment planning system. Adaptive plans consisted of a single VMAT with 6 MV flattening-filter-free (FFF) energy performed on a Varian TrueBeam linac. Pre-treatment verification of the adaptive "plan-of-the-day" (POD) created in each treatment session was performed using the Mobius 3D v. 3.1 secondary dose calculation program (M3D). Commissioning of M3D included the tuning of the dosimetric leaf gap correction (DLGc) parameter. Generic and specific DLGc values were then derived using a set of plans for typical sites (prostate, head and neck, brain, lung and bone palliative) and another set were determined for specific online SBRT PODs (gDLGc and sDLGc, respectively). The first 50 prostate patients treated with the PACE-B schedule (5 × 7.25 Gy) were included, i.e., 250 adaptive SBRT PODs were collected in this study. For each online adaptive POD, a global 3D gamma comparison between the Eclipse 3D dose and the M3D dose in the patient CBCT was performed. Gamma passing rates (GPRs) for the whole external patient contour (Body) and the PTV were recorded, using the 5 % global /3 mm criteria. The target mean dose and target coverage differences between the Eclipse and M3D doses were also analyzed (ΔDmean and ΔD90 %, respectively). The accuracy of M3D was assessed against PRIMO Monte Carlo software. Twenty-five online prostate SBRT PODs were randomly selected from the set of 250 adaptive plans and simulated with PRIMO. RESULTS Values of -1 mm and -0.14 mm were found as optimal gDLGc and sDLGc, respectively. Over the 250 online adaptive PODs, excellent GPR values ∼ 100 % were obtained for the Body and PTV structures, regardless the type of DLGc used. The use of the sDLGc instead of the gDLGc provided better results for ΔDmean (0.1 % ± 0.5% vs. -1.9 ± 0.7 %) and ΔD90 % (-1.0 % ± 0.5 %. vs. -3.5 % ± 0.8 %). This issue was also observed when M3D calculations were compared to PRIMO simulations. CONCLUSIONS M3D can be effectively used for independent pre-treatment verifications of online adaptive prostate SBRT plans. The use of a specific DLGc value is advised for this SBRT online adaptive technique.
Collapse
Affiliation(s)
- Juan-Francisco Calvo-Ortega
- Hospital Quirónsalud Barcelona. Servicio de Oncología Radioterápica, Plaza Alfonso Comín 5, 08023 Barcelona, Spain; Hospital Quirónsalud Málaga. Servicio de Oncología Radioterápica, Calle Pilar Lorengar 1, 29004 Málaga, Spain.
| | - Coral Laosa-Bello
- Hospital Quirónsalud Barcelona. Servicio de Oncología Radioterápica, Plaza Alfonso Comín 5, 08023 Barcelona, Spain
| | - Sandra Moragues-Femenía
- Hospital Quirónsalud Barcelona. Servicio de Oncología Radioterápica, Plaza Alfonso Comín 5, 08023 Barcelona, Spain
| | - Miguel Pozo-Massó
- Hospital Quirónsalud Barcelona. Servicio de Oncología Radioterápica, Plaza Alfonso Comín 5, 08023 Barcelona, Spain
| | - Adam Jones
- Hospital Quirónsalud Barcelona. Servicio de Oncología Radioterápica, Plaza Alfonso Comín 5, 08023 Barcelona, Spain; Hospital Quirónsalud Barcelona. Servicio de Radiofísica y Protección Radiológica. Plaza Alfonso Comín 5, 08023 Barcelona, Spain
| |
Collapse
|
7
|
Fischer J, Fischer LA, Bensberg J, Bojko N, Bouabdallaoui M, Frohn J, Hüttenrauch P, Tegeler K, Wagner D, Wenzel A, Schmitt D, Guhlich M, Leu M, El Shafie R, Stamm G, Schilling AF, Dröge LH, Rieken S. CBCT-based online adaptive radiotherapy of the prostate bed: first clinical experience and comparison to nonadaptive conventional IGRT. Strahlenther Onkol 2024:10.1007/s00066-024-02323-6. [PMID: 39499306 DOI: 10.1007/s00066-024-02323-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Accepted: 09/22/2024] [Indexed: 11/07/2024]
Abstract
PURPOSE Conventional image-guided radiotherapy (IGRT) of the prostate bed is challenged by the varying anatomy due to dynamic changes of surrounding organs such as the bladder and rectum. This leads to changed dose coverage of target and surrounding tissue. The novel online adaptive radiotherapy (oART) aims to improve target coverage as well as reduce dose exposure to surrounding healthy tissues by daily reoptimization of treatment plans. Here we set out to quantify the resulting changes of this adaptation for patients and treatment team. METHODS A total of 198 fractions of radiotherapy of the prostate bed (6 patients) were treated using oART with the Ethos accelerator (Varian Medical Systems, Palo Alto, CA, USA). For each fraction, volumes and several dose-volume parameters of target volumes and organs at risk were recorded for the scheduled plan (initial plan, recalculated based on daily cone beam computed tomography [CBCT]), the adapted plan, and the verification plan, which is the dose distribution of the applied plan recalculated on the closing CBCT after the adaptation process. Clinical acceptability for all plans was determined using given dose-volume parameters of target volumes. Additionally, the time needed for the adaptation process was registered and compared to the time required for the daily treatment of five conventional IGRT patients. RESULTS Volumes of target and organs at risk (OAR) exhibited broad variation from day to day. The differences in dose coverage D98% of the clinical target volume (CTV) were significant through adaptation (p < 0.0001; median D98% 97.1-98.0%) and further after verification CBCT (p < 0.001; median D98% 98.1%). Similarly, differences in D98% of the planning target volume (PTV) were significant with adaptation (p < 0.0001; median D98% 91.8-96.5%) and after verification CBCT (p < 0.001; median D98% 96.4%) with decreasing interquartile ranges (IQR). Dose to OAR varied extensively and did not show a consistent benefit from oART but decreased in IQR. Clinical acceptability increased significantly from 19.2% for scheduled plans to 76.8% for adapted plans and decreased to 70.7% for verification plans. The scheduled plan was never chosen for treatment. The median time needed for oART was 25 min compared to 8 min for IGRT. CONCLUSION Target dose coverage was significantly improved using oART. IQR decreased for target coverage as well as OAR doses indicating higher repeatability of dose delivery using oART. Differences in doses after verification CBCT for targets as well as OAR were significant compared to adapted plans but did not offset the overall dosimetric gain of oART. The median time required is three times higher for oART compared to IGRT.
Collapse
Affiliation(s)
- J Fischer
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany.
| | - L A Fischer
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - J Bensberg
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - N Bojko
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - M Bouabdallaoui
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - J Frohn
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - P Hüttenrauch
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - K Tegeler
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - D Wagner
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - A Wenzel
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - D Schmitt
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - M Guhlich
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - M Leu
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - R El Shafie
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - G Stamm
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
- Institute for Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
| | - A-F Schilling
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
- Department of Trauma Surgery, Orthopedics and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany
| | - L H Dröge
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| | - S Rieken
- Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
- Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany
| |
Collapse
|
8
|
Robert C, Meyer P, Séroussi B, Leroy T, Bibault JE. Artificial intelligence and radiotherapy: Evolution or revolution? Cancer Radiother 2024; 28:503-509. [PMID: 39406605 DOI: 10.1016/j.canrad.2024.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 08/31/2024] [Accepted: 09/01/2024] [Indexed: 11/03/2024]
Abstract
The integration of artificial intelligence, particularly deep learning algorithms, into radiotherapy represents a transformative shift in the field, enhancing accuracy, efficiency, and personalized care. This paper explores the multifaceted impact of artificial intelligence on radiotherapy, the evolution of the roles of radiation oncologists and medical physicists, and the associated practical challenges. The adoption of artificial intelligence promises to revolutionize the profession by automating repetitive tasks, improving diagnostic precision, and enabling adaptive radiotherapy. However, it also introduces significant risks, such as automation bias, verification failures, and the potential erosion of clinical skills. Ethical considerations, such as maintaining patient autonomy and addressing biases in artificial intelligence systems, are critical to ensuring the responsible use of artificial intelligence. Continuous training and development of robust quality assurance programs are required to mitigate these risks and maximize the benefits of artificial intelligence in radiotherapy.
Collapse
Affiliation(s)
- Charlotte Robert
- Inserm, U1030 Molecular Radiotherapy and Therapeutic Innovation, Université Paris-Saclay, Gustave-Roussy, Villejuif, France; Department of Radiation Oncology, Gustave-Roussy, Villejuif, France
| | - Philippe Meyer
- Department of Radiotherapy, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France; Icube, CNRS UMR 7357, team Images, Strasbourg, France
| | - Brigitte Séroussi
- Inserm, Laboratoire d'informatique médicale et d'ingénierie des connaissances en e-santé (Limics), Sorbonne université, université Sorbonne Paris Nord, 75006 Paris, France; Hôpital Tenon, AP-HP, Paris, France; Délégation ministérielle du numérique en santé, ministère de la Santé, Paris, France
| | - Thomas Leroy
- Department of Radiation Oncology, Centre de Cancérologie des Dentellières, Valenciennes, France.
| | - Jean-Emmanuel Bibault
- Department of Radiation Oncology, Hôpital Europeen Georges-Pompidou, AP-HP, Université Paris-Cité, Paris, France; Institut du Cancer Paris Carpem, Université Paris-Cité, AP-HP, Paris, France
| |
Collapse
|
9
|
Bookbinder A, Bobić M, Sharp GC, Nenoff L. An operator-independent quality assurance system for automatically generated structure sets. Phys Med Biol 2024; 69:175003. [PMID: 39047780 DOI: 10.1088/1361-6560/ad6742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2023] [Accepted: 07/23/2024] [Indexed: 07/27/2024]
Abstract
Objective. This study describes geometry-based and intensity-based tools for quality assurance (QA) of automatically generated structures for online adaptive radiotherapy, and designs an operator-independent traffic light system that identifies erroneous structure sets.Approach.A cohort of eight head and neck (HN) patients with daily CBCTs was selected for test development. Radiotherapy contours were propagated from planning computed tomography (CT) to daily cone beam CT (CBCT) using deformable image registration. These propagated structures were visually verified for acceptability. For each CBCT, several error scenarios were used to generate what were judged unacceptable structures. Ten additional HN patients with daily CBCTs and different error scenarios were selected for validation. A suite of tests based on image intensity, intensity gradient, and structure geometry was developed using acceptable and unacceptable HN planning structures. Combinations of one test applied to one structure, referred to as structure-test combinations, were selected for inclusion in the QA system based on their discriminatory power. A traffic light system was used to aggregate the structure-test combinations, and the system was evaluated on all fractions of the ten validation HN patients.Results.The QA system distinguished between acceptable and unacceptable fractions with high accuracy, labeling 294/324 acceptable fractions as green or yellow and 19/20 unacceptable fractions as yellow or red.Significance.This study demonstrates a system to supplement manual review of radiotherapy planning structures. Automated QA is performed by aggregating results from multiple intensity- and geometry-based tests.
Collapse
Affiliation(s)
- Alexander Bookbinder
- Department of Nuclear Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States of America
- New York Proton Center, New York, NY, United States of America
| | - Mislav Bobić
- ETH Zürich, Zürich, Switzerland
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States of America
- Harvard Medical School, Boston, MA, United States of America
| | - Gregory C Sharp
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States of America
- Harvard Medical School, Boston, MA, United States of America
| | - Lena Nenoff
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States of America
- Harvard Medical School, Boston, MA, United States of America
- OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany
| |
Collapse
|
10
|
Bobić M, Choulilitsa E, Lee H, Czerska K, Christensen JB, Mayor A, Safai S, Winey BA, Weber DC, Lomax AJ, Paganetti H, Nesteruk KP, Albertini F. Multi-institutional experimental validation of online adaptive proton therapy workflows. Phys Med Biol 2024; 69:165021. [PMID: 39025115 DOI: 10.1088/1361-6560/ad6527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Accepted: 07/18/2024] [Indexed: 07/20/2024]
Abstract
Objective.To experimentally validate two online adaptive proton therapy (APT) workflows using Gafchromic EBT3 films and optically stimulated luminescent dosimeters (OSLDs) in an anthropomorphic head-and-neck phantom.Approach.A three-field proton plan was optimized on the planning CT of the head-and-neck phantom with 2.0 Gy(RBE) per fraction prescribed to the clinical target volume. Four fractions were simulated by varying the internal anatomy of the phantom. Three distinct methods were delivered: daily APT researched by the Paul Scherrer Institute (DAPTPSI), online adaptation researched by the Massachusetts General Hospital (OAMGH), and a non-adaptive (NA) workflow. All methods were implemented and measured at PSI. DAPTPSIperformed full online replanning based on analytical dose calculation, optimizing to the same objectives as the initial treatment plan. OAMGHperformed Monte-Carlo-based online plan adaptation by only changing the fluences of a subset of proton beamlets, mimicking the planned dose distribution. NA delivered the initial plan with a couch-shift correction based on in-room imaging. For all 12 deliveries, two films and two sets of OSLDs were placed at different locations in the phantom.Main results.Both adaptive methods showed improved dosimetric results compared to NA. For film measurements in the presence of anatomical variations, the [min-max] gamma pass rates (3%/3 mm) between measured and clinically approved doses were [91.5%-96.1%], [94.0%-95.8%], and [67.2%-93.1%] for DAPTPSI, OAMGH, and NA, respectively. The OSLDs confirmed the dose calculations in terms of absolute dosimetry. Between the two adaptive workflows, OAMGHshowed improved target coverage, while DAPTPSIshowed improved normal tissue sparing, particularly relevant for the brainstem.Significance.This is the first multi-institutional study to experimentally validate two different concepts with respect to online APT workflows. It highlights their respective dosimetric advantages, particularly in managing interfractional variations in patient anatomy that cannot be addressed by non-adaptive methods, such as internal anatomy changes.
Collapse
Affiliation(s)
- Mislav Bobić
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Evangelia Choulilitsa
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Paul Scherrer Institute, Villigen, Switzerland
| | - Hoyeon Lee
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | | | | | | | | | - Brian A Winey
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Damien C Weber
- Paul Scherrer Institute, Villigen, Switzerland
- Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
- Department of Radiation Oncology, University Hospital Bern, University of Bern, Bern, Switzerland
| | - Antony J Lomax
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Paul Scherrer Institute, Villigen, Switzerland
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Konrad P Nesteruk
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | | |
Collapse
|
11
|
Qiu Z, Depauw N, Gorissen BL, Madden T, Ajdari A, den Hertog D, Bortfeld T. A reference-point-method-based online proton treatment plan re-optimization strategy and a novel solution to planning constraint infeasibility problem. Phys Med Biol 2024; 69:125001. [PMID: 38729194 DOI: 10.1088/1361-6560/ad4a00] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Accepted: 05/10/2024] [Indexed: 05/12/2024]
Abstract
Objective. Propose a highly automated treatment plan re-optimization strategy suitable for online adaptive proton therapy. The strategy includes a rapid re-optimization method that generates quality replans and a novel solution that efficiently addresses the planning constraint infeasibility issue that can significantly prolong the re-optimization process.Approach. We propose a systematic reference point method (RPM) model that minimizes the l-infinity norm from the initial treatment plan in the daily objective space for online re-optimization. This model minimizes the largest objective value deviation among the objectives of the daily replan from their reference values, leading to a daily replan similar to the initial plan. Whether a set of planning constraints is feasible with respect to the daily anatomy cannot be known before solving the corresponding optimization problem. The conventional trial-and-error-based relaxation process can cost a significant amount of time. To that end, we propose an optimization problem that first estimates the magnitude of daily violation of each planning constraint. Guided by the violation magnitude and clinical importance of the constraints, the constraints are then iteratively converted into objectives based on their priority until the infeasibility issue is solved.Main results.The proposed RPM-based strategy generated replans similar to the offline manual replans within the online time requirement for six head and neck and four breast patients. The average targetD95and relevant organ at risk sparing parameter differences between the RPM replans and clinical offline replans were -0.23, -1.62 Gy for head and neck cases and 0.29, -0.39 Gy for breast cases. The proposed constraint relaxation solution made the RPM problem feasible after one round of relaxation for all four patients who encountered the infeasibility issue.Significance. We proposed a novel RPM-based re-optimization strategy and demonstrated its effectiveness on complex cases, regardless of whether constraint infeasibility is encountered.
Collapse
Affiliation(s)
- Zihang Qiu
- Department of Business Analytics, University of Amsterdam, Amsterdam, The Netherlands
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Nicolas Depauw
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Bram L Gorissen
- The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Boston, MA, United States of America
- Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, United States of America
| | - Thomas Madden
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Ali Ajdari
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| | - Dick den Hertog
- Department of Business Analytics, University of Amsterdam, Amsterdam, The Netherlands
| | - Thomas Bortfeld
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America
| |
Collapse
|
12
|
Oud M, Breedveld S, Rojo-Santiago J, Giżyńska MK, Kroesen M, Habraken S, Perkó Z, Heijmen B, Hoogeman M. A fast and robust constraint-based online re-optimization approach for automated online adaptive intensity modulated proton therapy in head and neck cancer. Phys Med Biol 2024; 69:075007. [PMID: 38373350 DOI: 10.1088/1361-6560/ad2a98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 02/19/2024] [Indexed: 02/21/2024]
Abstract
Objective. In head-and-neck cancer intensity modulated proton therapy, adaptive radiotherapy is currently restricted to offline re-planning, mitigating the effect of slow changes in patient anatomies. Daily online adaptations can potentially improve dosimetry. Here, a new, fully automated online re-optimization strategy is presented. In a retrospective study, this online re-optimization approach was compared to our trigger-based offline re-planning (offlineTBre-planning) schedule, including extensive robustness analyses.Approach. The online re-optimization method employs automated multi-criterial re-optimization, using robust optimization with 1 mm setup-robustness settings (in contrast to 3 mm for offlineTBre-planning). Hard planning constraints and spot addition are used to enforce adequate target coverage, avoid prohibitively large maximum doses and minimize organ-at-risk doses. For 67 repeat-CTs from 15 patients, fraction doses of the two strategies were compared for the CTVs and organs-at-risk. Per repeat-CT, 10.000 fractions with different setup and range robustness settings were simulated using polynomial chaos expansion for fast and accurate dose calculations.Main results. For 14/67 repeat-CTs, offlineTBre-planning resulted in <50% probability ofD98%≥ 95% of the prescribed dose (Dpres) in one or both CTVs, which never happened with online re-optimization. With offlineTBre-planning, eight repeat-CTs had zero probability of obtainingD98%≥ 95%Dpresfor CTV7000, while the minimum probability with online re-optimization was 81%. Risks of xerostomia and dysphagia grade ≥ II were reduced by 3.5 ± 1.7 and 3.9 ± 2.8 percentage point [mean ± SD] (p< 10-5for both). In online re-optimization, adjustment of spot configuration followed by spot-intensity re-optimization took 3.4 min on average.Significance. The fast online re-optimization strategy always prevented substantial losses of target coverage caused by day-to-day anatomical variations, as opposed to the clinical trigger-based offline re-planning schedule. On top of this, online re-optimization could be performed with smaller setup robustness settings, contributing to improved organs-at-risk sparing.
Collapse
Affiliation(s)
- Michelle Oud
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
- HollandPTC, Department of Medical Physics & Informatics, Delft, The Netherlands
| | - Sebastiaan Breedveld
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
| | - Jesús Rojo-Santiago
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
- HollandPTC, Department of Medical Physics & Informatics, Delft, The Netherlands
| | | | - Michiel Kroesen
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
- HollandPTC, Department of Radiation Oncology, Delft, The Netherlands
| | - Steven Habraken
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
- HollandPTC, Department of Medical Physics & Informatics, Delft, The Netherlands
| | - Zoltán Perkó
- Delft University of Technology, Faculty of Applied Sciences, Department of Radiation Science and Technology, The Netherlands
| | - Ben Heijmen
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
| | - Mischa Hoogeman
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, The Netherlands
- HollandPTC, Department of Medical Physics & Informatics, Delft, The Netherlands
| |
Collapse
|
13
|
Fog LS, Webb LK, Barber J, Jennings M, Towns S, Olivera S, Shakeshaft J. ACPSEM position paper: pre-treatment patient specific plan checks and quality assurance in radiation oncology. Phys Eng Sci Med 2024; 47:7-15. [PMID: 38315415 DOI: 10.1007/s13246-023-01367-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 12/06/2023] [Indexed: 02/07/2024]
Abstract
The Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) has not previously made recommendations outlining the requirements for physics plan checks in Australia and New Zealand. A recent workforce modelling exercise, undertaken by the ACPSEM, revealed that the workload of a clinical radiation oncology medical physicist can comprise of up to 50% patient specific quality assurance activities. Therefore, in 2022 the ACPSEM Radiation Oncology Specialty Group (ROSG) set up a working group to address this issue. This position paper authored by ROSG endorses the recommendations of the American Association of Physicists in Medicine (AAPM) Task Group 218, 219 and 275 reports with some contextualisation for the Australia and New Zealand settings. A few recommendations from other sources are also endorsed to complete the position.
Collapse
Affiliation(s)
- Lotte S Fog
- Alfred Health Radiation Oncology, Melbourne, VIC, Australia.
| | | | - Jeffrey Barber
- Sydney West Radiation Oncology Network, Blacktown Hospital, Blacktown, NSW, 2148, Australia
| | - Matthew Jennings
- ICON Cancer Care, Cordelia St, South Brisbane, QLD, 4101, Australia
| | - Sam Towns
- Alfred Health Radiation Oncology, Melbourne, VIC, Australia
| | - Susana Olivera
- ICON Cancer Care, Liz Plummer Cancer Centre, Cairns, QLD, 4870, Australia
| | - John Shakeshaft
- ICON Cancer Care, Gold Coast University Hospital, 1 Hospital Blvd, Southport, QLD, 4215, Australia
| |
Collapse
|
14
|
Bobić M, Christensen JB, Lee H, Choulilitsa E, Czerska K, Togno M, Safai S, Yukihara EG, Winey BA, Lomax AJ, Paganetti H, Albertini F, Nesteruk KP. Optically stimulated luminescence dosimeters for simultaneous measurement of point dose and dose-weighted LET in an adaptive proton therapy workflow. Front Oncol 2024; 13:1333039. [PMID: 38510267 PMCID: PMC10951997 DOI: 10.3389/fonc.2023.1333039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 12/18/2023] [Indexed: 03/22/2024] Open
Abstract
Purpose To demonstrate the suitability of optically stimulated luminescence detectors (OSLDs) for accurate simultaneous measurement of the absolute point dose and dose-weighted linear energy transfer (LETD) in an anthropomorphic phantom for experimental validation of daily adaptive proton therapy. Methods A clinically realistic intensity-modulated proton therapy (IMPT) treatment plan was created based on a CT of an anthropomorphic head-and-neck phantom made of tissue-equivalent material. The IMPT plan was optimized with three fields to deliver a uniform dose to the target volume covering the OSLDs. Different scenarios representing inter-fractional anatomical changes were created by modifying the phantom. An online adaptive proton therapy workflow was used to recover the daily dose distribution and account for the applied geometry changes. To validate the adaptive workflow, measurements were performed by irradiating Al2O3:C OSLDs inside the phantom. In addition to the measurements, retrospective Monte Carlo simulations were performed to compare the absolute dose and dose-averaged LET (LETD) delivered to the OSLDs. Results The online adaptive proton therapy workflow was shown to recover significant degradation in dose conformity resulting from large anatomical and positioning deviations from the reference plan. The Monte Carlo simulations were in close agreement with the OSLD measurements, with an average relative error of 1.4% for doses and 3.2% for LETD. The use of OSLDs for LET determination allowed for a correction for the ionization quenched response. Conclusion The OSLDs appear to be an excellent detector for simultaneously assessing dose and LET distributions in proton irradiation of an anthropomorphic phantom. The OSLDs can be cut to almost any size and shape, making them ideal for in-phantom measurements to probe the radiation quality and dose in a predefined region of interest. Although we have presented the results obtained in the experimental validation of an adaptive proton therapy workflow, the same approach can be generalized and used for a variety of clinical innovations and workflow developments that require accurate assessment of point dose and/or average LET.
Collapse
Affiliation(s)
- Mislav Bobić
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | | | - Hoyeon Lee
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Evangelia Choulilitsa
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Paul Scherrer Institute, Villigen, Switzerland
| | | | | | | | | | - Brian A. Winey
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | - Antony J. Lomax
- Department of Physics, ETH Zurich, Zurich, Switzerland
- Paul Scherrer Institute, Villigen, Switzerland
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| | | | - Konrad P. Nesteruk
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States
| |
Collapse
|
15
|
Galand A, Prunaretty J, Mir N, Morel A, Bourgier C, Aillères N, Azria D, Fenoglietto P. Feasibility study of adaptive radiotherapy with Ethos for breast cancer. Front Oncol 2023; 13:1274082. [PMID: 38023141 PMCID: PMC10679322 DOI: 10.3389/fonc.2023.1274082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 10/26/2023] [Indexed: 12/01/2023] Open
Abstract
Purpose The aim of this study was to assess the feasibility of online adaptive radiotherapy with Ethos for breast cancer. Materials and methods This retrospective study included 20 breast cancer patients previously treated with TrueBeam. All had undergone breast surgery for different indications (right/left, lumpectomy/mastectomy) and were evenly divided between these four cases, with five extended cone beam computed tomography (CBCT) scans per patient. The dataset was used in an Ethos emulator to test the full adaptive workflow. The contours generated by artificial intelligence (AI) for the influencers (left and right breasts and lungs, heart) and elastic or rigid propagation for the target volumes (internal mammary chain (IMC) and clavicular lymph nodes (CLNs)) were compared to the initial contours delineated by the physician using two metrics: Dice similarity coefficient (DICE) and Hausdorff 95% distance (HD95). The repeatability of influencer generation was investigated. The times taken by the emulator to generate contours, optimize plans, and calculate doses were recorded. The quality of the scheduled and adapted plans generated by Ethos was assessed using planning target volume (PTV) coverage, homogeneity indices (HIs), and doses to organs at risk (OARs) via dose-volume histogram (DVH) metrics. Quality assurance (QA) of the treatment plans was performed using an independent portal dosimetry tool (EpiQA) and gamma index. Results On average, the DICE for the influencers was greater than 0.9. Contours resulting from rigid propagation had a higher DICE and a lower HD95 than those resulting from elastic deformation but remained below the values obtained for the influencers: DICE values were 0.79 ± 0.11 and 0.46 ± 0.17 for the CLN and IMC, respectively. Regarding the repeatability of the influencer segmentation, the DICE was close to 1, and the mean HD95 was strictly less than 0.15 mm. The mean time was 73 ± 4 s for contour generation per AI and 80 ± 9 s for propagations. The average time was 53 ± 3 s for dose calculation and 125 ± 9 s for plan optimization. A dosimetric comparison of scheduled and adapted plans showed a significant difference in PTV coverage: dose received by 95% of the volume (D95%) values were higher and closer to the prescribed doses for adapted plans. Doses to organs at risk were similar. The average gamma index for quality assurance of adapted plans was 99.93 ± 0.38 for a 3%/3mm criterion. Conclusion This study comprehensively evaluated the Ethos® adaptive workflow for breast cancer and its potential technical limitations. Although the results demonstrated the high accuracy of AI segmentation and the superiority of adapted plans in terms of target volume coverage, a medical assessment is still required.
Collapse
Affiliation(s)
| | - Jessica Prunaretty
- Radiotherapy Department, Montpellier Regional Cancer Institute, Montpellier, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Lee D, Renz P, Oh S, Hwang MS, Pavord D, Yun KL, Collura C, McCauley M, Colonias A(T, Trombetta M, Kirichenko A. Online Adaptive MRI-Guided Stereotactic Body Radiotherapy for Pancreatic and Other Intra-Abdominal Cancers. Cancers (Basel) 2023; 15:5272. [PMID: 37958447 PMCID: PMC10648954 DOI: 10.3390/cancers15215272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 10/31/2023] [Accepted: 11/01/2023] [Indexed: 11/15/2023] Open
Abstract
A 1.5T MRI combined with a linear accelerator (Unity®, Elekta; Stockholm, Sweden) is a device that shows promise in MRI-guided stereotactic body radiation treatment (SBRT). Previous studies utilized the manufacturer's pre-set MRI sequences (i.e., T2 Weighted (T2W)), which limited the visualization of pancreatic and intra-abdominal tumors and organs at risk (OAR). Here, a T1 Weighted (T1W) sequence was utilized to improve the visualization of tumors and OAR for online adapted-to-position (ATP) and adapted-to-shape (ATS) during MRI-guided SBRT. Twenty-six patients, 19 with pancreatic and 7 with intra-abdominal cancers, underwent CT and MRI simulations for SBRT planning before being treated with multi-fractionated MRI-guided SBRT. The boundary of tumors and OAR was more clearly seen on T1W image sets, resulting in fast and accurate contouring during online ATP/ATS planning. Plan quality in 26 patients was dependent on OAR proximity to the target tumor and achieved 96 ± 5% and 92 ± 9% in gross tumor volume D90% and planning target volume D90%. We utilized T1W imaging (about 120 s) to shorten imaging time by 67% compared to T2W imaging (about 360 s) and improve tumor visualization, minimizing target/OAR delineation uncertainty and the treatment margin for sparing OAR. The average time-consumption of MRI-guided SBRT for the first 21 patients was 55 ± 15 min for ATP and 79 ± 20 min for ATS.
Collapse
Affiliation(s)
- Danny Lee
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| | - Paul Renz
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
| | - Seungjong Oh
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| | - Min-Sig Hwang
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| | - Daniel Pavord
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| | - Kyung Lim Yun
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
| | - Colleen Collura
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
| | - Mary McCauley
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
| | - Athanasios (Tom) Colonias
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
| | - Mark Trombetta
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| | - Alexander Kirichenko
- Radiation Oncology, Allegheny Health Network, Pittsburgh, PA 15012, USA; (P.R.); (S.O.); (M.-S.H.); (D.P.); (K.L.Y.); (C.C.); (M.M.); (M.T.); (A.K.)
- College of Medicine, Radiologic Sciences/Drexel University, Philadelphia, PA 19129, USA
| |
Collapse
|
17
|
Velonis M, Papanastasiou E, Hatziioannou K, Siountas A, Kamperis E, Papavasileiou P, Koukourakis MI, Seimenis I. Dose optimization of 2D X-ray image acquisition protocols in image-guided radiotherapy. Phys Med 2023; 115:103161. [PMID: 37847953 DOI: 10.1016/j.ejmp.2023.103161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 09/06/2023] [Accepted: 10/06/2023] [Indexed: 10/19/2023] Open
Abstract
PURPOSE In contemporary radiotherapy, patient positioning accuracy relies on kV imaging. This study aims at optimizing planar kV image acquisition protocols regarding patient dose without degrading image quality. MATERIALS AND METHODS An image quality test-object was placed in-between PMMA plates, suitably arranged to model head or pelvis. Constructed phantoms were imaged using default protocols, the resultant image quality was assessed and the corresponding radiation dose was measured. The process was repeated using numerous kV/mAs combinations to identify those acquisition settings providing images at lower dose than the default protocols but without deterioration in image quality. Default and dose-optimized protocols were then tested on an anthropomorphic phantom and on 51 patients during two successive treatment sessions. Image quality was independently assessed by two readers. Organ and effective doses were estimated using a Monte Carlo simulation software. RESULTS Low-contrast detectability exhibited a stronger dependence on kV/mAs settings, compared to high-contrast resolution. Dose-optimized protocols resulted in significant dose reductions (anteroposterior-head 48.0 %, lateral-head 30.0 %, anteroposterior-pelvis 28.4 %, lateral-pelvis 27.0 %) compared to the default ones, without compromising image quality. Optimized protocols decreased effective doses by 54 % and 29.6 % in head and pelvic acquisitions, respectively. Regarding image quality, anthropomorphic and patient images acquired using the dose-optimized protocols were subjectively evaluated equivalent to those obtained with the corresponding default settings, indicating that the proposed protocols may be routinely used. CONCLUSIONS Given the potentially large number of radiotherapy fractions and the pertinent image acquisitions, dose-optimized protocols could significantly reduce patient dose associated with planar imaging without compromising positioning accuracy.
Collapse
Affiliation(s)
- Marios Velonis
- Department of Medicine, Faculty of Health Sciences, Democritus University of Thrace, Greece; Department of Medical Physics, Papageorgiou General Hospital, Thessaloniki, Greece.
| | - Emmanouil Papanastasiou
- Medical Physics & Digital Innovation Laboratory, Medical School, Aristotle University of Thessaloniki, Greece
| | | | - Anastasios Siountas
- Medical Physics & Digital Innovation Laboratory, Medical School, Aristotle University of Thessaloniki, Greece
| | - Efstathios Kamperis
- Department of Radiotherapy, Papageorgiou General Hospital, Thessaloniki, Greece
| | - Periklis Papavasileiou
- Department of Biomedical Sciences, School of Health Sciences, University of West Attica, Greece
| | - Michael I Koukourakis
- Department of Medicine, Faculty of Health Sciences, Democritus University of Thrace, Greece
| | - Ioannis Seimenis
- Medical Physics Laboratory, School of Medicine, National and Kapodistrian University of Athens, Greece
| |
Collapse
|
18
|
Knäusl B, Taasti VT, Poulsen P, Muren LP. Surveying the clinical practice of treatment adaptation and motion management in particle therapy. Phys Imaging Radiat Oncol 2023; 27:100457. [PMID: 37361612 PMCID: PMC10285555 DOI: 10.1016/j.phro.2023.100457] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2023] Open
Affiliation(s)
- Barbara Knäusl
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
| | - Vicki T Taasti
- Department of Radiation Oncology (Maastro), GROW - School for Oncology and Reproduction, Maastricht, University Medical Centre+, Maastricht, The Netherlands
| | - Per Poulsen
- Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
- Department of Oncology, Aarhus University, Aarhus, Denmark
| | - Ludvig P Muren
- Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|